Found: 140
Select item for more details and to access through your institution.
Exploration of the Product of the 5-Point Investigator's Global Assessment and Body Surface Area (IGA × BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM).
- Published in:
- 2018
- By:
- Publication type:
- journal article
Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis Registry.
- Published in:
- Clinical & Experimental Dermatology, 2024, v. 49, n. 9, p. 1016, doi. 10.1093/ced/llae095
- By:
- Publication type:
- Article
Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials.
- Published in:
- International Journal of Dermatology, 2016, v. 55, n. 4, p. 401, doi. 10.1111/ijd.13236
- By:
- Publication type:
- Article
Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis.
- Published in:
- International Journal of Dermatology, 2016, v. 55, n. 3, p. e147, doi. 10.1111/ijd.13117
- By:
- Publication type:
- Article
256 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).
- Published in:
- Rheumatology, 2018, v. 57, n. 10, p. 1777, doi. 10.1093/rheumatology/key161
- By:
- Publication type:
- Article
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
- Published in:
- Rheumatology, 2017, v. 56, n. 11, p. 1993, doi. 10.1093/rheumatology/kex301
- By:
- Publication type:
- Article
Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2005, v. 9, n. 6, p. 313, doi. 10.1007/s10227-005-0117-0
- By:
- Publication type:
- Article
Alefacept Is Well Tolerated in Patients With Chronic Plaque Psoriasis.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2004, v. 8, p. 14, doi. 10.1177/12034754040080S204
- By:
- Publication type:
- Article
Alefacept is Well Tolerated in Patients with Chronic Plaque Psoriasis.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2004, v. 8, p. 14, doi. 10.1177/12034754040080S204
- By:
- Publication type:
- Article
A Case of Familial Psoriasis with Predominant Hand Involvement.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2003, v. 7, n. 6, p. 464, doi. 10.1007/s10227-002-0150-1
- By:
- Publication type:
- Article
Subcutaneously Administered Efalizumab (Anti-CD11a) Improves Signs and Symptoms of Moderate to Severe Plaque Psoriasis.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2003, v. 7, n. 3, p. 198, doi. 10.1007/s10227-002-0118-1
- By:
- Publication type:
- Article
The Efficacy and Tolerability of Clobetasol Propionate Foam 0.05% in the Treatment of Mild to Moderate Plaque-type Psoriasis of Nonscalp Regions.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2003, v. 7, n. 3, p. 185, doi. 10.1007/s10227-002-0114-5
- By:
- Publication type:
- Article
Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
- Published in:
- Therapeutic Advances in Musculoskeletal Disease, 2021, p. 1, doi. 10.1177/1759720X211057975
- By:
- Publication type:
- Article
Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes.
- Published in:
- Journal of Cutaneous Pathology, 1996, v. 23, n. 5, p. 404, doi. 10.1111/j.1600-0560.1996.tb01430.x
- By:
- Publication type:
- Article
Fixed drug eruptions: evidence for a cytokine-mediated process.
- Published in:
- Journal of Cutaneous Pathology, 1991, v. 18, n. 1, p. 13, doi. 10.1111/j.1600-0560.1991.tb00596.x
- By:
- Publication type:
- Article
Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 6, p. 1615, doi. 10.1007/s13555-024-01188-y
- By:
- Publication type:
- Article
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 3, p. 729, doi. 10.1007/s13555-024-01122-2
- By:
- Publication type:
- Article
Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors Associated with the Development of Psoriatic Arthritis: Retrospective Analysis of a US Claims Database.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 11, p. 2635, doi. 10.1007/s13555-023-01025-8
- By:
- Publication type:
- Article
Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 8, p. 1831, doi. 10.1007/s13555-023-00969-1
- By:
- Publication type:
- Article
Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT Survey.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 6, p. 1329, doi. 10.1007/s13555-023-00929-9
- By:
- Publication type:
- Article
Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2).
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2).
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 1, p. 315, doi. 10.1007/s13555-022-00861-4
- By:
- Publication type:
- Article
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 4, p. 911, doi. 10.1007/s13555-022-00704-2
- By:
- Publication type:
- Article
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 2, p. 495, doi. 10.1007/s13555-021-00649-y
- By:
- Publication type:
- Article
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 5, p. 1551, doi. 10.1007/s13555-021-00570-4
- By:
- Publication type:
- Article
Musculoskeletal Imaging for Dermatologists: Techniques in the Diagnosis and Management of Psoriatic Arthritis.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 4, p. 1199, doi. 10.1007/s13555-021-00565-1
- By:
- Publication type:
- Article
Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis.
- Published in:
- Dermatology & Therapy, 2020, v. 10, n. 6, p. 1255, doi. 10.1007/s13555-020-00434-3
- By:
- Publication type:
- Article
Clinical Goals and Barriers to Effective Psoriasis Care.
- Published in:
- Dermatology & Therapy, 2019, v. 9, n. 1, p. 5, doi. 10.1007/s13555-018-0279-5
- By:
- Publication type:
- Article
The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS).
- Published in:
- Dermatology & Therapy, 2018, v. 8, n. 1, p. 45, doi. 10.1007/s13555-017-0213-2
- By:
- Publication type:
- Article
The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health.
- Published in:
- Dermatology & Therapy, 2018, v. 8, n. 1, p. 33, doi. 10.1007/s13555-017-0212-3
- By:
- Publication type:
- Article
Differential Expression of Phosphorylated NF-κB/RelA in Normal and Psoriatic Epidermis and Downregulation of NF-κB in Response to Treatment with Etanercept.
- Published in:
- Journal of Investigative Dermatology, 2005, v. 124, n. 6, p. 1275, doi. 10.1111/j.0022-202X.2005.23735.x
- By:
- Publication type:
- Article
Identification of Aberrantly Regulated Genes in Diseased Skin Using the cDNA Differential Display Technique.
- Published in:
- Journal of Investigative Dermatology, 1997, v. 108, n. 2, p. 188, doi. 10.1111/1523-1747.ep12334217
- By:
- Publication type:
- Article
The Insulin-like Growth Factor 1 Receptor Is Expressed by Epithelial Cells with Proliferative Potential in Human Epidermis and Skin Appendages: Correlation of Increased Expression with Epidermal Hyperplasia.
- Published in:
- Journal of Investigative Dermatology, 1996, v. 106, n. 3, p. 564, doi. 10.1111/1523-1747.ep12344044
- By:
- Publication type:
- Article
GM-CSF Activates Regenerative Epidermal Growth and Stimulates Keratinocyte Proliferation in Human Skin <em>In Vivo</em>.
- Published in:
- Journal of Investigative Dermatology, 1994, v. 103, n. 4, p. 601, doi. 10.1111/1523-1747.ep12396936
- By:
- Publication type:
- Article
Anthralin Decreases Keratinocyte TGF-α Expression and EGF-Receptor Binding In Vitro.
- Published in:
- Journal of Investigative Dermatology, 1992, v. 98, n. 5, p. 680, doi. 10.1111/1523-1747.ep12499901
- By:
- Publication type:
- Article
Studies of the Effect of Cyclosporine in Psoriasis In Vivo: Combined Effects on Activated T Lymphocytes and Epidermal Regenerative Maturation.
- Published in:
- Journal of Investigative Dermatology, 1992, v. 98, n. 3, p. 302, doi. 10.1111/1523-1747.ep12499782
- By:
- Publication type:
- Article
Increased Dermal Expression of Platelet-Derived Growth Factor Receptors in Growth-Activated Skin Wounds and Psoriasis.
- Published in:
- Journal of Investigative Dermatology, 1991, v. 96, n. 6, p. 983, doi. 10.1111/1523-1747.ep12476485
- By:
- Publication type:
- Article
Immunologic Mechanisms in Psoriasis.
- Published in:
- Journal of Investigative Dermatology, 1990, v. 95, n. 5, p. 18S, doi. 10.1111/1523-1747.ep12505675
- By:
- Publication type:
- Article
Role of Growth Factors, Cytokines, and Their Receptors in the Pathogenesis of Psoriasis.
- Published in:
- Journal of Investigative Dermatology, 1990, v. 94, p. 135s, doi. 10.1111/1523-1747.ep12876121
- By:
- Publication type:
- Article
RNA, DNA, and Cell Surface Characteristics of Lesional and Nonlesional Psoriatic Skin.
- Published in:
- Journal of Investigative Dermatology, 1987, v. 88, n. 5, p. 646, doi. 10.1111/1523-1747.ep12470257
- By:
- Publication type:
- Article
Purification and In Vitro Growth of Human Epidermal Basal Keratinocytes Using a Monoclonal Antibody.
- Published in:
- Journal of Investigative Dermatology, 1985, v. 85, n. 4, p. 299, doi. 10.1111/1523-1747.ep12276866
- By:
- Publication type:
- Article
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial.
- Published in:
- Advances in Therapy, 2021, v. 38, n. 10, p. 5253, doi. 10.1007/s12325-021-01836-1
- By:
- Publication type:
- Article
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study.
- Published in:
- Arthritis & Rheumatology, 2022, v. 74, n. 12, p. 1959, doi. 10.1002/art.42280
- By:
- Publication type:
- Article
Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis
- Published in:
- Arthritis & Rheumatology, 2022, v. 74, n. 3, p. 475, doi. 10.1002/art.42010
- By:
- Publication type:
- Article
Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis.
- Published in:
- Arthritis & Rheumatology, 2021, v. 73, n. 4, p. 604, doi. 10.1002/art.41553
- By:
- Publication type:
- Article
The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.
- Published in:
- Arthritis & Rheumatology, 2016, v. 68, n. 9, p. 2163, doi. 10.1002/art.39700
- By:
- Publication type:
- Article